{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-228016","form_type":"8-K","ticker":"SLNO","cik":"0001484565","company_name":"SOLENO THERAPEUTICS INC","filed_at":"2026-05-18T13:06:24+00:00","discovered_at":"2026-05-18T13:07:00.155839+00:00","generated_at":"2026-05-18T13:10:44.990317+00:00","sec_items":["1.02","2.01","3.01","3.03","5.01","5.02","5.03","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Soleno acquisition by Neurocrine Biosciences completed; all shares bought for $53.00 each","bullets":["Tender offer expired May 15 with 88.9% of shares tendered; merger closed May 18, 2026.","Stockholders received $53.00 per share in cash; total offer consideration funded via Neurocrine cash.","All pre-merger directors and officers resigned; new directors and officers from Neurocrine appointed.","Shares to be delisted from Nasdaq and deregistered with SEC; Form 15 to be filed.","Loan agreement with Oxford Finance and 2014 ESPP terminated effective upon merger."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-228016","json":"https://secwatch.observer/filing/0001193125-26-228016.json","markdown":"https://secwatch.observer/filing/0001193125-26-228016.md","text":"https://secwatch.observer/filing/0001193125-26-228016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526228016/0001193125-26-228016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526228016/d143266d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T13:10:44.990317+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"00a9059a04","claim":"Patricia Hirano resigned as Senior Vice President, Regulatory Affairs at SOLENO THERAPEUTICS INC.","evidence_excerpt":"each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526228016/0001193125-26-228016-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Senior Vice President, Regulatory Affairs"}],"fact_type":"executive_change"},{"claim_id":"09aad6d38e","claim":"Mark Hahn resigned as Director at SOLENO THERAPEUTICS INC.","evidence_excerpt":"each of Anish Bhatnagar, M.D., Mark Hahn, Matthew Pauls, Birgitte Volck, Andrew Sinclair and Dawn Bir resigned from his or her respective positions as a member of the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526228016/0001193125-26-228016-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"1f4262e266","claim":"Andrew Sinclair resigned as Director at SOLENO THERAPEUTICS INC.","evidence_excerpt":"each of Anish Bhatnagar, M.D., Mark Hahn, Matthew Pauls, Birgitte Volck, Andrew Sinclair and Dawn Bir resigned from his or her respective positions as a member of the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526228016/0001193125-26-228016-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"3e61dbb9f3","claim":"Anish Bhatnagar resigned as Chief Executive Officer at SOLENO THERAPEUTICS INC.","evidence_excerpt":"each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526228016/0001193125-26-228016-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"4aa8c832fa","claim":"Anish Bhatnagar resigned as Director at SOLENO THERAPEUTICS INC.","evidence_excerpt":"each of Anish Bhatnagar, M.D., Mark Hahn, Matthew Pauls, Birgitte Volck, Andrew Sinclair and Dawn Bir resigned from his or her respective positions as a member of the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526228016/0001193125-26-228016-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"52b0d00af1","claim":"Kristen Yen resigned as Senior Vice President, Global Clinical Operations & Patient Advocacy at SOLENO THERAPEUTICS INC.","evidence_excerpt":"each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526228016/0001193125-26-228016-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Senior Vice President, Global Clinical Operations & Patient Advocacy"}],"fact_type":"executive_change"},{"claim_id":"5c377aa966","claim":"Darin M. Lippoldt was appointed as President and Secretary at SOLENO THERAPEUTICS INC.","evidence_excerpt":"the officers of the Company are as follows: Darin M. Lippoldt (President and Secretary) and Matthew C. Abernethy (Treasurer and Vice President).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526228016/0001193125-26-228016-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Secretary"}],"fact_type":"executive_change"},{"claim_id":"5e09b5abbc","claim":"Matthew Pauls resigned as Director at SOLENO THERAPEUTICS INC.","evidence_excerpt":"each of Anish Bhatnagar, M.D., Mark Hahn, Matthew Pauls, Birgitte Volck, Andrew Sinclair and Dawn Bir resigned from his or her respective positions as a member of the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526228016/0001193125-26-228016-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6846d9ed47","claim":"Jennifer Fulk resigned as Chief Financial Officer at SOLENO THERAPEUTICS INC.","evidence_excerpt":"each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526228016/0001193125-26-228016-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"721566fc74","claim":"Kevin Norrett resigned as Chief Business Officer at SOLENO THERAPEUTICS INC.","evidence_excerpt":"each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526228016/0001193125-26-228016-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Business Officer"}],"fact_type":"executive_change"},{"claim_id":"840e47b4fe","claim":"Matthew C. Abernethy was appointed as Treasurer and Vice President at SOLENO THERAPEUTICS INC.","evidence_excerpt":"the officers of the Company are as follows: Darin M. Lippoldt (President and Secretary) and Matthew C. Abernethy (Treasurer and Vice President).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526228016/0001193125-26-228016-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Treasurer and Vice President"}],"fact_type":"executive_change"},{"claim_id":"8a40ab2fbb","claim":"Matthew C. Abernethy was appointed as Director at SOLENO THERAPEUTICS INC.","evidence_excerpt":"Immediately following the Effective Time, Matthew C. Abernethy and Darin M. Lippoldt became the directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526228016/0001193125-26-228016-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9131e6b293","claim":"Meredith Manning resigned as Chief Commercial Officer at SOLENO THERAPEUTICS INC.","evidence_excerpt":"each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526228016/0001193125-26-228016-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"},{"claim_id":"dcd6ea6658","claim":"Manher (AJ) Joshi resigned as Chief Development Officer at SOLENO THERAPEUTICS INC.","evidence_excerpt":"each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526228016/0001193125-26-228016-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Development Officer"}],"fact_type":"executive_change"},{"claim_id":"e0c8f2097c","claim":"Birgitte Volck resigned as Director at SOLENO THERAPEUTICS INC.","evidence_excerpt":"each of Anish Bhatnagar, M.D., Mark Hahn, Matthew Pauls, Birgitte Volck, Andrew Sinclair and Dawn Bir resigned from his or her respective positions as a member of the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526228016/0001193125-26-228016-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ee96226ef1","claim":"Michael Huang resigned as Senior Vice President, Clinical Development at SOLENO THERAPEUTICS INC.","evidence_excerpt":"each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526228016/0001193125-26-228016-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Senior Vice President, Clinical Development"}],"fact_type":"executive_change"},{"claim_id":"f0909ba425","claim":"Darin M. Lippoldt was appointed as Director at SOLENO THERAPEUTICS INC.","evidence_excerpt":"Immediately following the Effective Time, Matthew C. Abernethy and Darin M. Lippoldt became the directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526228016/0001193125-26-228016-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f529da00e2","claim":"Dawn Bir resigned as Director at SOLENO THERAPEUTICS INC.","evidence_excerpt":"each of Anish Bhatnagar, M.D., Mark Hahn, Matthew Pauls, Birgitte Volck, Andrew Sinclair and Dawn Bir resigned from his or her respective positions as a member of the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526228016/0001193125-26-228016-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"5b62f22ef2493866d0c09bf4186ace897310791b","claim":"SOLENO THERAPEUTICS INC: The company's bylaws were amended and restated in their entirety.","evidence_excerpt":"the Company’s certificate of incorporation and bylaws were each amended and restated in their entirety","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526228016/0001193125-26-228016-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"65c794e0641087166a3cbb69b62ad107a9292508","claim":"SOLENO THERAPEUTICS INC: The company's certificate of incorporation was amended and restated in its entirety.","evidence_excerpt":"the Company’s certificate of incorporation and bylaws were each amended and restated in their entirety","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526228016/0001193125-26-228016-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"f24cb8c6e76890338ff20d21993b0b187fd9aab8","claim":"SOLENO THERAPEUTICS INC underwent a change of control involving Neurocrine Biosciences, Inc. for $53.00 per Share in cash (closed 2026-05-18).","evidence_excerpt":"a tender offer (the “Offer”) to purchase all of the issued and outstanding shares of the common stock of the Company, par value $0.001 per share (the “Shares”), in exchange for $53.00 per Share in cash, without interest (the “Offer Price”), subject to any applicable withholding taxes. The Offer expired as scheduled one minute following 11:59 p.m. Eastern Time","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526228016/0001193125-26-228016-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Neurocrine Biosciences, Inc."},{"label":"Consideration","value":"$53.00 per Share in cash"},{"label":"Closing","value":"2026-05-18"}],"fact_type":"ma_transaction"},{"claim_id":"02825979590abf190e7c7aa06f6b42be2c509548","claim":"SOLENO THERAPEUTICS INC terminated 2014 Employee Stock Purchase Plan.","evidence_excerpt":"In accordance with the terms of the Merger Agreement, effective immediately prior to the Effective Time, the Company terminated its 2014 Employee Stock Purchase Plan (the \"ESPP\").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526228016/0001193125-26-228016-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"equity purchase"}],"fact_type":"material_agreement"},{"claim_id":"16130134130f1ae796aef39f512f56e946cf19ee","claim":"SOLENO THERAPEUTICS INC terminated Loan and Security Agreement with Oxford Finance LLC, as collateral agent (effective 2026-05-18).","evidence_excerpt":"On May 18, 2026, in connection with the Merger, the Company, as borrower, terminated the Loan and Security Agreement, dated as of December 17, 2024, as amended, by and among the Company, Essentialis, Inc., the lenders from time to time party thereto and Oxford Finance LLC, as collateral agent (the \"Loan and Security Agreement\").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526228016/0001193125-26-228016-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Oxford Finance LLC, as collateral agent"},{"label":"Effective","value":"2026-05-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}